Method for detecting RNA biomarkers

• Main Authors: STEINKUEHLER CHRISTIAN, FOSSATI GIANLUCA, RIPAMONTI CHIARA
• Format: Patent
• Language: Chinese; English
• Published: 14.06.2024
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; VINEGAR; WINE

The present invention relates to a method based on mRNA biomarkers that can be used to determine the effective dose and/or biological activity of a histone deacetylase 6 (HDAC6) inhibitor, such as the compound N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl) methyl) benzamide, during the clinical treatment of a patient affected by cancer. More specifically, the present invention relates to the analysis of changes in gene expression of specific biomarkers in human monocytes as "gene expression imprint" in methods of assessing the clinical efficacy of HDAC6 inhibitors, such as the compound N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl) methyl) benzamide. 本发明涉及一种基于mRNA生物标志物的方法，其可在受癌症影响的患者的临床治疗期间用于测定组蛋白去乙酰酶6(HDAC6)抑制剂(如化合物N-羟基-4-((5-(噻吩-2-基)-1H-四唑-1-基)甲基)苯甲酰胺)的有效剂量和/或生物活性。更具体而言，本发明涉及在评估HDAC6抑制剂(如化合物N-羟基-4-((5-(噻吩-2-基)-1H-四唑-1-基)甲基)苯甲酰胺)临床疗效的方法中，分析在人单核细胞中特定生物标志物的基因表达的变化作为"基因表达印记"。